→ The global contract genomics outfit WuXi NextCODE raised a $75 million B round from an international consortium of investors. Amgen Ventures was involved, along with 3W Partners in a raise led by Temasek and Yunfeng Capital. “Genomics is the crossroad where data and biology meet,” said Ge Li, chairman of WuXi NextCODE and founder and chairman of WuXi AppTec.
→ Angling to hit the clinic in 2019 with new immuno-oncology drugs, France’s ImCheck has raised a €20 million Series A round led by Boehringer Ingelheim Venture Fund, Kurma Partners, Idinvest and joined by Gimv and LSP. Based in Marseilles, the company is focused on gamma-delta T cells. The biotech also appointed Pierre d’Epenoux as chief executive officer.
→ Intec Pharma $NTEC says that Zeev Weiss has resigned as chief executive officer and a director of the company “to pursue other professional opportunities.” Weiss will serve as a clinical and business development consultant to Intec Pharma and the board appointed Giora Carni, a director since 2006 and chief executive officer of Intec Pharma from 2006 to 2014, as interim chief executive officer while a search for a new chief executive officer has begun.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription